A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer

Inclusion Criteria

• Histologically confirmed advanced/metastatic hepatocellular carcinoma (HCC)
• Naïve to systemic therapy for advanced/metastatic HCC (prior neo-adjuvant or adjuvant immunotherapy is permitted if recurrence occurs ≥ 6 months after treatment completion and the case is discussed with BMS medical team)
• Child-Pugh score of 5 or 6 (ie, Child-Pugh A)
• Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

Exclusion Criteria

• Known fibrolamellar HCC, sarcomatoid HCC or mixed cholangiocarcinoma and HCC
• Prior allogenic stem cell or solid organ transplantation
• Untreated symptomatic central nervous system (CNS) metastases
• Clinically significant ascites as defined by: i) Prior ascites that required treatment and requires on-going prophylaxis, or ii) Current ascites requiring treatment Other protocol-defined inclusion/exclusion criteria apply